FTSE 100 finishes a whisker from record high as BoE points to gradual rate hike
The FTSE 100 closed out Thursday up around 67 points at 7,555.
Company
ImmuPharma PLC
LON:IMM
ImmuPharma PLC is a biopharmaceutical company that specializes in the usage and development of biopolymers, specifically peptides. The company is dedicated to developing an innovative portfolio of peptide-based therapeutic drugs with a focus on autoimmunity/inflammation and anti-infectives.
305 stories · page 3 of 4
Archive
Small caps movers - Health care companies take centre stage with Advanced Oncotherapy a notable mover
The big mover, up 64%, was Advanced Oncotherapy, which is building a next-generation proton therapy system
Archive
Proactive news snapshot: Motif Bio, AdEPT Telecom, Landore Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Future PLC raises expectations as chairman signals intention to bow out
Peter Allen will not be going back to the Future board room after February's AGM
ImmuPharma banks extra £600,000 from Lanstead agreement
The better-than-expected outcome reflects a trebling in the share price of Immupharma
FTSE 100 barely changed after PM's speech; Centrica slides
Not much happening among the blue-chips but Image Scan and Future were among the big movers in the small caps sector
Archive
Proactive news snapshot: Ergomed , PCF Group, Synairgen …
A glance at some of the day's highlights from the Proactive Investors newswire
Imaginatik lifted by contract win with US investment management company
"We continue to believe that in order for an organisation to build and sustain a business-critical innovation ethos and competency, technology and consultancy need to be implemented in a joined-up way," said Imaginatik
ImmuPharma interims chart period of significant progress for lead drug
Lupuzor is currently undergoing a phase III clinical trial 200 in patients in the US, Europe and Mauritius
FTSE 100 steadily extends gains
There has been no news flow from FTSE 100 companies to speak of today
Archive
Proactive news snapshot: Victoria Oil & Gas, Eco (Atlantic), Highlands Natural Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Nostra Terra doubles as it secures hedging facility with BP
"I am particularly pleased to confirm funds released through the hedging facility will not carry any geographical restrictions. This means we will be able to deploy capital across our entire portfolio," said CEO, Matt Lofgran
Immupharma starts preparations for Lupuzor submission as trial makes good progress
Decision to start to manufacture commercial batches was taken in anticipation of the trial's successful outcome and to exploit 'fast track' status'
Archive
Proactive news snapshot: Active Energy Group, 88 Energy, Amryt Pharma …
A glance at some of the day's highlights from the Proactive Investors newswire
Safestyle UK rallies as it signals intention to buy back shares
Safestyle UK has more cash than it needs at present
ImmuPharma says more than a quarter of patients have now completed phase III lupus trial
We’ll know how effective Lupuzor is when the top line data is shared with the market in the first quarter of next year
ImmuPharma says 90% of patients have pass six-month milestone on key lupus trial
In all 200 suffers were recruited to the trial and all of them have now past the three month stage.
Archive
Proactive news round-up: Kibo Mining, SDX Energy, Eland OIl...
A summary of some of the small cap stories on the Proactive newswire
Satellite group Inmarsat rockets on takeover speculation
Some of the main risers and fallers in London at 3.45pm...
ImmuPharma says lead lupus drug development programme on track to deliver results in the first quarter of 2017
Lupuzor, for the autoimmune disease lupus, is undergoing phase III clinical trials.
FTSE 100 closes higher; Paddy Power Betfair takes podium
After a gloomy morning for the pound, it started to build some momentum. FTSE 100 finished at 7,543
Archive
High Court to hear whether RBS rights issue case should proceed to trial
Day ahead: RBS likely to avert High Court trial; finals from FirstGroup, Johnson Matthey and ImmuPharma
Archive
Fourth-quarter improvement hoped for from IG Group
Week ahead; IG Group, Ryanair, Johnson Matthey, Non-Farm Payrolls,
Archive
Proactive news round-up: Nasstar, Redx Pharma, Keywords Studios...
A glance at some of the stories on the Proactive newswire...
BP ticks higher as shareholders back CEO's reduced pay at AGM
A look at some of the biggest London-listed risers and fallers today
ImmuPharma says Lupuzor trial in 'new territory' and on schedule
The trial runs for twelve months and 28 patients have now received the full dosage and 166 (80%) six months' worth
FTSE 100 closes lower as Trump fears grow; Dow Jones crashes
The UK blue chip index closed down 18.56 points at 7,503
Legal & General ups stake in ImmuPharma
L&G upped its stake in the recent £4.1mln fundraising, and now holds a 3.5% stake in ImmuPharma
Advanced Oncotherapy rallies on funding update
Some of the largest rises and falls in London at 10.00am: SynairGen, BOS Global, Angus Energy
Drug developer ImmuPharma raises £4.1mln in oversubscribed placing
The life sciences group said the accelerated book-build offering saw around 7.884 mln new shares placed at 52p each, a modest discount to last night’s closing share price
FTSE 100 ends higher as BT declares Openreach plans, US jobs gain
FTSE 100 stocks ended higher on Friday, led by telecoms behemoth BT after confirming it would separate Openreach
Archive
Proactive news round-up: Minds + Machines, Kromek Group, Clinigen Group …
A glance at some of the stories on the Proactive newswire today.
ImmuPharma "grossly undervalued", says broker as co updates on trial
Analyst Vadim Alexandre, of the company’s broker Northland Capital, said Wednesday’s update provided “better visibility” on the trial timetable.
ImmuPharma update reveals strong demand to take part in phase III lupus trial
In all 293 patients were screened to take part in the study and 200 were accepted.
Four drug stocks to watch in phase III next year
2017 could be a big year for these four lesser-known junior drug developers
Archive
Proactive news round-up: Abenza, Falcon Oil & Gas, Aviation ...
A glance at some of the stories on the Proactive newswire today
ImmuPharma passes "major milestone" as it completes recruitment for phase III Lupus trial
It has delivered on its plan to have 200 sufferers of the life-threatening auto-immune disease taking part in the study by the end of the year.
FTSE edges higher, small caps help London record 40% gainers, miners sink
FTSE 100 stocks ended higher on Thursday after pulling away from flat positions at midsession while small-caps helped 40% of London’s stocks to gain – one of their best performances this year - but falling prices for copper, zinc and nickel
Archive
Brokers: 25% upside as well as big yield at Imperial Brands
A round-up of some of today's broker commentary
Immupharma among the small cap pharmas in focus on Wednesday
Immupharma among the small cap pharmas in focus on Wednesday, alongside Futura Medical, Horizon Discovery Group, and Summit Therapeutics.
ImmuPharma’s valuation “way too low”
One analyst thinks the drug discoverer could add at least another £1 to its share price
Legal & General revealed as ImmuPharma backer
L&G has a 3.43% stake after participating in the drug developer's well-supported share placing earlier this year
Proactive news highlights: Mosman stars as it acquires producing oil field
Also in the news, Hurricane Energy has started drilling on its latest well in the North Sea, while Premier African hits ‘significant’ lithium grades in Zimbabwe
ImmuPharma tops up funds as Lupuzor trial progresses
Immupharma said that this cash would be used on lupus treatment Lupuzor
Proactive news highlights: Ariana Resources, Cello Group, ImmuPharma, Premier African and more...
Serial small cap promoter David Lenigas gets behind Premier African, Falcon Oil & Gas reports “excellent gas shows”, and slot machine software group Quixant hits the jackpot with half-year results.
Proactive news highlights: Base Resources, Galileo Resources, ImmuPharma, Sound Energy and more...
Daily round up of the day's news headlines from Proactive Investors.
Immupharma to recruit patients from Mauritius
The request to open a new site came directly from the government following a visit to the island nation by the drug’s inventor, professor Sylviane Muller.
Archive
Brokers: Barclays bullish on financial services
The bank has picked out several banking and financial stocks that it likes the look of, although Barclays has had its own stock downgraded by UBS
Proactive news highlights, including SolGold, W Resources and Challenger Acquisitions
A mixed news bag but small cap miners appeared to be out in force
Immupharma drug has billion dollar potential - Northland
It is a potential blockbuster, said the broker, which targets 171p for the share.
Immupharma moves forward with Lupus drug trials
Drug company said it had started dosing Lupus sufferers with Lupuzor
Archive
Small caps highlights: Aim stocks largely dodge blue-chip blues
Take Aim. London’s growth stocks have been immune to the negativity dogging the market for blue-chip shares.
Shot in the arm for ImmuPharma as shares spike 67%
Up more 67% in last five trading sessions it has been on the rampage since it was revealed that Alto Invest had taken its stake to 4.15%.
Blue-chip shares slide while Aim stocks thrive
The FTSE 100 surrendered all of May's gains to close 10 points down on the month
Small-cap pharma stocks rise but FTSE 100 Index treads water
The FTSE 100 Index trod water as traders shrugged off mixed economic data from the continent
Proactive news highlights: Diamondcorp, Forbidden Technologies, Gemfields,..
ITM Power announced that London's first hydrogen refuelling station is to open next week, Westminster Group awaits the arrival of the Sierra Princess and Deltex Medical reconfigures its probe tip.
ImmuPharma has its eye on the prize
"ImmuPharma is focused on ensuring the successful development of the late stage clinical development of Lupuzor through its pivotal phase III trial,” chairman Tim McCarthy told investors.
Sainsbury's results put UK retail under spotlight again
As if the UK retail sector hadn't had enough coverage last week, it's now the turn of Sainsbury's....
Hopes rise for AIM drug breakthroughs
A trio of AIM companies are putting potential new drugs through phase three trials
Immupharma PLC recruiting in Europe for Lupus trial
Recruiting patients in Europe has now begun for the pivotal phase III trial of Lupuzor, the firm said.
Archive
Proactive news summary: Amur, Aureus, Forbidden, Purecircle and more...
Horse Hill off to the races, Forbidden technologies extends contract and PureCircle doubles earnings.
Immupharma confirms £8.4mln fundraise
Shares in ImmuPharma nudged higher as it confirmed it had raised a total £8.4mln to advance the potential blockbuster drug Lupuzor.
Immupharma updates on successful placing
Drug discovery firm ImmuPharma has raised £7.7mln from the previously announced fundraise and is due to receive a further £0.7mln from advance assurances.
Archive
Proactive news summary: Windar Photonics, 88 Energy, Metal Tiger, Egdon Resources and more.
Everything appears to being going to plan for 88 Energy in Alaska...
ImmuPharma passes landmark as phase III dosing starts
In all clinical trials will take place across 45 locations – 10 in America, the rest in Europe.
ImmuPharma raises £8.3mln to fund potential blockbuster
The company will use cash to fund its share of costs of developing Lupuzor, the potential blockbuster drug for autoimmune disease Lupus, which is undergoing phase III clinical trials.
Investments and investor services
Proactive news highlights: ANGLE, Motive Television, Utilitywise and more...
Weatherly International, Motif Bio and 88 energy also had news out on Tuesday
ImmuPharma rolling on rapidly with Lupuzor
Lupuzor is not the only part of the Immupharma story and McCarthy plans also to raise the profile of the rest of the group's early stage pipeline in 2016.....
ImmuPharma meeting brings together Lupus specialists
ImmuPharma was host to 70 investigators and senior coordinators from the US and Europe who will be involved in the pivotal phase-III trial of Lupuzor...
Risers & Fallers: Amur Minerals, Immupharma, Rosslyn Data and more...
Below are the main news-driven share price movements at 4pm
Investments and investor services
Markets: Oil stocks push FTSE100 lower
The FTSE100 ended the day almost 15 points lower to 6,223.
Investments and investor services
Proactive news highlights: IOG, Motif Bio, allergy Therapeutics, ReNeuron, Immupharma and more
Sunrise Resources, Optibiotix Health and ITM Power also had news out
Investments and investor services
Risers & Fallers: Immupharma, Kenmare, Pinnacle and more
Below are the main news-driven share price movements at 4pm.
Archive
Proactive news summary: Allergy Therapeutics, Berkeley Energy, Forbidden Technologies, Gemfields ...
Pride of place goes to Plethora Solutions, after Jim Mellon's Regent Pacific offered to take it over.
ImmuPharma spells out plans for phase III clinical trial
The study, being carried out with the help of clinical research firm Simbec-Orion, will take place at 45 different sites – 10 in the US, 35 in Europe.
Investments and investor services
Proactive news highlights: Venn Life Sciences, Optibiotix, Petropavlovsk, Mart, 88 Energy and more
Pharma companies and energy firms were in the news today...
ImmuPharma non-executive director bows out
Dr Ajay Agrawal is to step down with immediate effect
Archive
Proactive news highlights - Strategic Minerals, ServicePower, Bushveld Minerals, Iona Energy and Summit Therapeutics
If you're a fan of interim results statements, today was dedicated to you.
ImmuPharma's chairman passes away
Richard Warr, co-founder and chairman of ImmuPharma, has died.